A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis
A D Fraser, A W R van Kuijk, R Westhovens, Z Karim, R Wakefield, A H Gerards, R Landewé, S D Steinfeld, P Emery, B A C Dijkmans, D J Veale, A D Fraser, A W R van Kuijk, R Westhovens, Z Karim, R Wakefield, A H Gerards, R Landewé, S D Steinfeld, P Emery, B A C Dijkmans, D J Veale
Abstract
Objectives: To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to methotrexate (MTX) monotherapy.
Methods: In a 12 month, randomised, double blind, placebo controlled trial at five centres in three countries, 72 patients with active PsA with an incomplete response to MTX were randomised to receive either CSA (n = 38) or placebo (n = 34). Patients underwent full clinical and radiological assessment and, in addition, high resolution ultrasound (HRUS) was performed at one centre. An intention to treat (last observation carried forward) analysis was employed.
Results: Some significant improvements were noted at 12 months in both groups. However, in the active but not the placebo arm there were significant improvements in swollen joint count, mean (SD), from 11.7 (9.7) to 6.7 (6.5) (p<0.001) and C reactive protein, from 17.4 (14.5) to 12.7 (14.3) mg/l (p<0.05) as compared with baseline. The Psoriasis Area and Severity Index (PASI) score improved in the active group (2 (2.3) to 0.8 (1.3)) as compared with placebo (2.2 (2.7) to 1.9 (2.8)), p<0.001, and synovitis detected by HRUS (33 patients, 285 joints) was reduced by 33% in the active group compared with 6% in the placebo group (p<0.05). No improvement in Health Assessment Questionnaire or pain scores was detected.
Conclusions: Synovitis detected by HRUS was significantly reduced. Combining CSA and MTX treatment in patients with active PsA, and a partial response to MTX, significantly improves the signs of inflammation but not pain or quality of life.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1755527/bin/ar24463.f1.jpg)
Figure 2
Percentage of joints with synovitis…
Figure 2
Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks.…
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Antoni CE, et al. Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. Arthritis Rheum. 2005. PMID: 15818699 Clinical Trial.
- Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P. Quinn MA, et al. Arthritis Rheum. 2005 Jan;52(1):27-35. doi: 10.1002/art.20712. Arthritis Rheum. 2005. PMID: 15641102 Clinical Trial.
- A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB; 990145 Study Group. Cohen SB, et al. Ann Rheum Dis. 2004 Sep;63(9):1062-8. doi: 10.1136/ard.2003.016014. Epub 2004 Apr 13. Ann Rheum Dis. 2004. PMID: 15082469 Free PMC article. Clinical Trial.
- Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J. Doyle MK, et al. Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Semin Arthritis Rheum. 2009. PMID: 18823645 Review.
- Therapy with cyclosporine in psoriatic arthritis.Olivieri I, Salvarani C, Cantini F, Macchioni L, Padula A, Niccoli L, Boiardi L, Portioli I. Olivieri I, et al. Semin Arthritis Rheum. 1997 Aug;27(1):36-43. doi: 10.1016/s0049-0172(97)80035-2. Semin Arthritis Rheum. 1997. PMID: 9287388 Review.
- Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review.Hsieh TS, Tsai TF. Hsieh TS, et al. Dermatol Ther (Heidelb). 2023 Apr;13(4):891-909. doi: 10.1007/s13555-023-00903-5. Epub 2023 Mar 21. Dermatol Ther (Heidelb). 2023. PMID: 36943580 Free PMC article. Review.
- Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil.Faria RJ, Cordeiro FJR, Dos Santos JBR, Alvares-Teodoro J, Guerra Júnior AA, Acurcio FA, da Silva MRR. Faria RJ, et al. Front Pharmacol. 2022 Apr 26;13:878972. doi: 10.3389/fphar.2022.878972. eCollection 2022. Front Pharmacol. 2022. PMID: 35559237 Free PMC article.
- Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process.García-Vicuña R, Garrido N, Gómez S, Joven B, Queiro R, Ramírez J, Rebollo F, Loza E, Sellas A. García-Vicuña R, et al. Rheumatol Int. 2021 Sep;41(9):1549-1565. doi: 10.1007/s00296-021-04877-5. Epub 2021 May 2. Rheumatol Int. 2021. PMID: 33934175 Free PMC article.
- Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.Singh SK, Singnarpi SR. Singh SK, et al. Indian J Dermatol Venereol Leprol. 2021 Mar-Apr;87(2):214-222. doi: 10.25259/IJDVL_613_19. Indian J Dermatol Venereol Leprol. 2021. PMID: 33769732 Clinical Trial.
- Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.Rombach I, Tillett W, Jadon D, Tucker L, Watson M, Francis A, Sinomati Y, Eldridge L, Dritsaki M, Dutton SJ, Al-Mossawi H, Gullick N, Thompson B, Coates LC. Rombach I, et al. Trials. 2021 Mar 4;22(1):185. doi: 10.1186/s13063-021-05142-7. Trials. 2021. PMID: 33663566 Free PMC article.
- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Adolescent
- Adult
- Aged
- Antirheumatic Agents / therapeutic use*
- Arthritis, Psoriatic / drug therapy*
- Arthritis, Psoriatic / pathology
- Cyclosporine / therapeutic use*
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Immunosuppressive Agents / therapeutic use*
- Male
- Methotrexate / therapeutic use*
- Middle Aged
- Quality of Life
- Severity of Illness Index
- Treatment Outcome
- Antirheumatic Agents
- Immunosuppressive Agents
- Cyclosporine
- Methotrexate
- Full Text Sources
- Medical
- Research Materials
- Miscellaneous
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1755527/bin/ar24463.f2.jpg)
References
- J Rheumatol. 2001 Oct;28(10):2274-82
- JAMA. 1964 Sep 7;189:743-7
- J Rheumatol. 2003 Feb;30(2):260-8
- BioDrugs. 2003;17(4):263-70
- N Engl J Med. 2003 Aug 14;349(7):658-65
- Semin Arthritis Rheum. 2003 Aug;33(1):29-37
- Arthritis Rheum. 2003 Nov;48(11):3085-95
- Rheumatology (Oxford). 2003 Dec;42(12):1460-8
- Acta Radiol Diagn (Stockh). 1977 Jul;18(4):481-91
- Dermatologica. 1978;157(4):238-44
- J Rheumatol. 1982 Sep-Oct;9(5):789-93
- Acta Derm Venereol. 1983;63(2):165-7
- Arthritis Rheum. 1984 Apr;27(4):376-81
- Acta Derm Venereol. 1987;67(3):270-3
- Q J Med. 1987 Feb;62(238):127-41
- Arch Dermatol. 1989 Apr;125(4):507-10
- J Rheumatol. 1990 Jun;17(6):809-12
- J Rheumatol. 1992 Jun;19(6):872-7
- Allerg Immunol (Paris). 1992 Dec;24(10):393-4
- Dermatology. 1993;186(1):62-7
- Arthritis Rheum. 1993 Jun;36(6):729-40
- Br J Rheumatol. 1994 Feb;33(2):133-8
- Acta Derm Venereol Suppl (Stockh). 1994;186:116-7
- Acta Derm Venereol Suppl (Stockh). 1994;186:94-5
- N Engl J Med. 1995 Jul 20;333(3):137-41
- Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589-93
- Br J Dermatol. 1996 Nov;135(5):752-7
- Curr Opin Rheumatol. 1997 Jul;9(4):295-301
- Arthritis Rheum. 1997 Oct;40(10):1868-72
- Exp Hematol. 1998 Dec;26(13):1215-22
- Arthritis Rheum. 1999 Jun;42(6):1232-45
- Br J Dermatol. 1999 Aug;141(2):279-82
- Ann Rheum Dis. 1999 Oct;58(10):595-7
- Arthritis Rheum. 2002 Jan;46(1):124-9
Source: PubMed